TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3567466

Group type: EXPERIMENTAL
Intervention: CT with 16.25 g iodine contrast medium
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: CT with 32.5 g iodine contrast medium
Number of subjects: 45

Group type: COMPARATOR
Intervention: CT without intravenous contrast medium
Number of subjects: 45
Study: 31048295

Group type: COMPARATOR
Intervention: Epidural lidocaine alone
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Epidural corticosteroid and lidocaine
Number of subjects: 350
Study: 29798249

Group type: EXPERIMENTAL
Intervention: Patient controlled intravenous analgesia (Group A)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Ibuprofen (5 mg/kg/sub) (Group B)
Number of subjects: 124
Study: 23146277

Group type: EXPERIMENTAL
Intervention: Therapeutic conversation intervention (2-5 sessions with a nurse)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Standard family nursing care (control group)
Number of subjects: 136
Study: 21908460

Group type: EXPERIMENTAL
Intervention: Abrupt quitting with nicotine lozenge, quit date set between 1 and 3 weeks after study onset.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gradual quitting with nicotine lozenge, quit date set between 3 and 5 weeks after study entry.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quit after planned quit date.
Number of subjects: 0
Study: 19196319

Group type: EXPERIMENTAL
Intervention: 1.0% amine fluoride fluid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.5% amine fluoride fluid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16488057

Group type: EXPERIMENTAL
Intervention: 2‐L pulse lavage normal saline washout
Number of subjects: 0

Group type: COMPARATOR
Intervention: 2‐L normal saline washout via a jug or a syringe
Number of subjects: 0
Study: 15615236

Group type: EXPERIMENTAL
Intervention: Brochure provided to patients (case group)
Number of subjects: 54

Group type: COMPARATOR
Intervention: No brochure provided (control group)
Number of subjects: 54
Study: 11918093

Group type: EXPERIMENTAL
Intervention: Virtual reality training with conflicting visual-vestibular stimulation (VVS) for 45 minutes
Number of subjects: 24
Study: 8856712

Group type: EXPERIMENTAL
Intervention: Adenosine (low dose)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Adenosine (increasing doses)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 1727765

Group type: EXPERIMENTAL
Intervention: Immediate refeeding (regular diet immediately)
Number of subjects: 258

Group type: COMPARATOR
Intervention: Delayed refeeding (nothing by mouth for 36 hours, then clear liquids for 12 hours, and a regular diet thereafter)
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Immediate refeeding
Number of subjects: 258

Group type: COMPARATOR
Intervention: Delayed refeeding
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Rebleeding in patients with clean-based ulcers
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Rebleeding in patients with ulcers with spots
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Rebleeding in patients with ulcers with clots
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Rebleeding in patients with Mallory-Weiss tears
Number of subjects: 258
Study: 6094373

Group type: EXPERIMENTAL
Intervention: NaHCO3 (0.2 g/kg B.W.)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: NaHCO3
Number of subjects: 11

Group type: COMPARATOR
Intervention: NaCl (placebo)
Number of subjects: 11
Study: 31155474

Group type: EXPERIMENTAL
Intervention: Calorie Group (calorie-tracking DSM app)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Photo Group (photo DSM app)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 41
Study: 27049826

Group type: EXPERIMENTAL
Intervention: Hydromorphone (up to 3 times daily for 6 months)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Diacetylmorphine (up to 3 times daily for 6 months)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Hydromorphone
Number of subjects: 202

Group type: COMPARATOR
Intervention: Diacetylmorphine
Number of subjects: 202
Study: 25057155

Group type: EXPERIMENTAL
Intervention: 60 mg Fe with water
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 60 mg Fe with food
Number of subjects: 32

Group type: COMPARATOR
Intervention: 6 mg Fe with food
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 60 mg Fe without food
Number of subjects: 32
Study: 22192729

Group type: EXPERIMENTAL
Intervention: Intravenous aflibercept (4 mg/kg every 2 weeks)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Intravenous aflibercept
Number of subjects: 55
Study: 20184211

Group type: EXPERIMENTAL
Intervention: Clobetasol propionate shampoo 0.05%
Number of subjects: 217

Group type: COMPARATOR
Intervention: Vehicle (placebo)
Number of subjects: 217
Study: 17097649

Group type: EXPERIMENTAL
Intervention: Intramuscular methotrexate 50 mg/m(2) administered on days 0 and 4; additional doses on day 7 and/or day 11 if hCG levels did not decrease by 15%
Number of subjects: 101
Study: 16199417

Group type: EXPERIMENTAL
Intervention: Single-injection thoracic paravertebral block with bupivacaine 0.375% and adrenaline 1:200 000 0.4 ml kg(‐1) plus i.v. patient‐controlled analgesia (PCA) with morphine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group treated with back puncture without injection and morphine PCA
Number of subjects: 40
Study: 12115221

Group type: EXPERIMENTAL
Intervention: Laser-based imaging technique
Number of subjects: 22
Study: 10619912

Group type: EXPERIMENTAL
Intervention: Gastric adenocarcinoma samples
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Diffuse adenocarcinomas
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Intestinal type gastric adenocarcinoma
Number of subjects: 85

Group type: COMPARATOR
Intervention: Normal gastric mucosa specimens
Number of subjects: 85
Study: 7478700

Group type: EXPERIMENTAL
Intervention: 50 mg oral tramadol
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: 100 mg oral tramadol
Number of subjects: 144

Group type: COMPARATOR
Intervention: 1000 mg paracetamol + 60 mg codeine (active control)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study: 1545135

Group type: EXPERIMENTAL
Intervention: Sphingosines (D-sphingosine, D,L-sphinganine, 4-D-hydroxysphinganine, oleoyl-sphingosine, N,N-dimethylsphingosine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sphingosines (erythro- and threo-isomers)
Number of subjects: 0
Study: 6366276

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30762613

Group type: EXPERIMENTAL
Intervention: 18 ECG replicates within a 3‐minute window
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 14 ECG replicates
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Concentration‐effect analysis
Number of subjects: 100
Study: 29119559

Group type: EXPERIMENTAL
Intervention: Preoperative intravenous methylprednisolone (MP) 125 mg
Number of subjects: 70

Group type: COMPARATOR
Intervention: Isotonic saline (control group)
Number of subjects: 70
Study: 26850208

Group type: EXPERIMENTAL
Intervention: First-person-shooter game (ShotG)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Surgery game (SurgG)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Racing game (RaceG)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control and/or nongaming (ContG)
Number of subjects: 20
Study: 23828016

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided intra-articular injection
Number of subjects: 80

Group type: COMPARATOR
Intervention: Palpation-guided intra-articular injection
Number of subjects: 80
Study: 20489027

Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir 400/100 mg twice daily coadministered with S/GSK1349572 30 mg once daily for 14 days
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: darunavir/ritonavir 600/100 mg twice daily coadministered with S/GSK1349572 30 mg once daily for 14 days
Number of subjects: 31

Group type: COMPARATOR
Intervention: S/GSK1349572 30 mg once daily
Number of subjects: 31
Study: 19288566

Group type: COMPARATOR
Intervention: e‐CE intervention
Number of subjects: 15

Group type: COMPARATOR
Intervention: multicomponent e‐CE intervention
Number of subjects: 15
Study: 17106401

Group type: EXPERIMENTAL
Intervention: COAS G200 Aberrometer
Number of subjects: 2394

Group type: COMPARATOR
Intervention: Canon RK‐F1 Autorefractor
Number of subjects: 2394
Study: 15095653

Group type: EXPERIMENTAL
Intervention: Intensive treatment of all cardiovascular risk factors
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Multi‐intensive group
Number of subjects: 15
Study: 11342895

Group type: EXPERIMENTAL
Intervention: Tolterodine 2 mg twice daily
Number of subjects: 378

Group type: COMPARATOR
Intervention: Oxybutynin 2.5 mg twice daily (increased to 5 mg after 2 weeks)
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: Tolterodine
Number of subjects: 378

Group type: COMPARATOR
Intervention: Oxybutynin
Number of subjects: 378
Study: 9204803

Group type: EXPERIMENTAL
Intervention: Foot Waffle (commercial heel elevation device)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Hospital pillows
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Foot Waffle
Number of subjects: 52

Group type: COMPARATOR
Intervention: Pillow
Number of subjects: 52
Study: 1539476

Group type: COMPARATOR
Intervention: Propofol anaesthesia (Group G)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Paracervical blockade with midazolam (Group R)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Mepivacaine concentration (Group R)
Number of subjects: 59

Group type: COMPARATOR
Intervention: p-deletion score (Group G)
Number of subjects: 59
Study: 3886311

Group type: EXPERIMENTAL
Intervention: Prophylactic treatment with penicillin/pivampicillin
Number of subjects: 474

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 474

Group type: EXPERIMENTAL
Intervention: Women with a history of pelvic inflammatory disease (PID)
Number of subjects: 474

Group type: EXPERIMENTAL
Intervention: Women with postabortal infection
Number of subjects: 474
Study: 30995174

Group type: COMPARATOR
Intervention: Pelvic Radiation Therapy (RT) at 45 to 50.4 Gy over 5 weeks
Number of subjects: 601

Group type: EXPERIMENTAL
Intervention: Vaginal Cuff Brachytherapy plus Paclitaxel/Carboplatin (VCB/C)
Number of subjects: 601
Study: 29374733

Group type: EXPERIMENTAL
Intervention: Rectus sheath block (RSB) analgesia - single-dose
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Rectus sheath block (RSB) analgesia - repeated-dose
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Rectus sheath block (RSB) analgesia - continuous infusion
Number of subjects: 56

Group type: COMPARATOR
Intervention: No RSB (control group)
Number of subjects: 56
Study: 26045170

Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg • kg(-1) anhydrous caffeine)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (artificial sweetener)
Number of subjects: 10
Study: 25440232

Group type: EXPERIMENTAL
Intervention: Bone injection gun (BIG)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: EZ‐IO
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Jamshidi
Number of subjects: 107
Study: 22211640

Group type: EXPERIMENTAL
Intervention: 10 mg rosuvastatin
Number of subjects: 1415

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1415

Group type: EXPERIMENTAL
Intervention: NGAL tertile
Number of subjects: 1415

Group type: EXPERIMENTAL
Intervention: NGAL
Number of subjects: 1415
Study: 20645509

Group type: EXPERIMENTAL
Intervention: Hyperbaric 0.5% bupivacaine (3 ml)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Isobaric 0.5% bupivacaine (3 ml)
Number of subjects: 60
Study: 18541900

Group type: EXPERIMENTAL
Intervention: Dasatinib 100 mg once daily
Number of subjects: 670

Group type: COMPARATOR
Intervention: Dasatinib 70 mg twice daily
Number of subjects: 670
Study: 15955951

Group type: EXPERIMENTAL
Intervention: NT 201 (70 to 300 U)
Number of subjects: 463

Group type: COMPARATOR
Intervention: BOTOX (70 to 300 U)
Number of subjects: 463
Study: 11807147

Group type: EXPERIMENTAL
Intervention: CHOP plus rituximab
Number of subjects: 399

Group type: COMPARATOR
Intervention: CHOP alone
Number of subjects: 399
Study: 10075337

Group type: EXPERIMENTAL
Intervention: Oral biotin (2.1 micromol)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Oral biotin (8.2 micromol)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Oral biotin (81.9 micromol)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Intravenous biotin (18.4 micromol)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: All doses of biotin (oral and intravenous)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Intravenous biotin and largest oral dose
Number of subjects: 6
Study: 7669468

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 20
Study: 2124311

Group type: EXPERIMENTAL
Intervention: Combined anaesthesia with PDA and intubation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Balanced fentanyl analgesia
Number of subjects: 20
Study: 434682

Group type: EXPERIMENTAL
Intervention: Single drug regimen (beta-lactam antibiotic)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Combination antibiotic regimen (beta-lactam antibiotic + aminoglycoside)
Number of subjects: 25
Study: 31690187

Group type: EXPERIMENTAL
Intervention: Pain at rest at baseline
Number of subjects: 48
Study: 27359179

Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise
Number of subjects: 28

Group type: COMPARATOR
Intervention: Very light-intensity exercise
Number of subjects: 28
Study: 25578255

Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab or aflibercept (fixed regimen for 48 weeks followed by flexible regimen until week 96)
Number of subjects: 1240

Group type: EXPERIMENTAL
Intervention: Flexible pro re nata (PRN) regimen after fixed regimen
Number of subjects: 1240
Study: 23667587

Group type: EXPERIMENTAL
Intervention: Multi-Biomarker Disease Activity (MBDA) test with educational materials
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group (no MBDA test information)
Number of subjects: 81
Study: 21857273

Group type: EXPERIMENTAL
Intervention: Single-injection sciatic nerve block (Fs group)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Continuous sciatic nerve block (FCS group)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Patient-controlled analgesia via femoral nerve catheter alone (F group)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: All groups (F, Fs, FCS)
Number of subjects: 90
Study: 18718986

Group type: EXPERIMENTAL
Intervention: Etanercept added to methotrexate monotherapy
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Methotrexate added to etanercept monotherapy
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Combination therapy (etanercept + methotrexate)
Number of subjects: 210
Study: 17300874

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Twelve Step Facilitation
Number of subjects: 78
Study: 15487477

Group type: EXPERIMENTAL
Intervention: Yoga group (20 sessions)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (cooperative activities)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Yoga group
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Yoga group (home practice)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Motion Logger Actigraph
Number of subjects: 19
Study: 11307743

Group type: EXPERIMENTAL
Intervention: Ultrasonic nebulization of iloprost
Number of subjects: 18

Group type: COMPARATOR
Intervention: Jet nebulization of iloprost
Number of subjects: 18
Study: 9568470

Group type: EXPERIMENTAL
Intervention: Gemfibrozil treatment
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 8047708

Group type: EXPERIMENTAL
Intervention: Shooting at 8-ft basket
Number of subjects: 74

Group type: COMPARATOR
Intervention: Shooting at 10-ft basket
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Self-efficacy prior to shooting at 8-ft basket
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Self-efficacy prior to shooting
Number of subjects: 74
Study: 3132364

Group type: EXPERIMENTAL
Intervention: FreAmine
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: F080
Number of subjects: 51
Study: 31645288

Group type: EXPERIMENTAL
Intervention: Regional anaesthesia‐analgesia (paravertebral blocks and propofol)
Number of subjects: 2132

Group type: COMPARATOR
Intervention: General anaesthesia (sevoflurane) and opioid analgesia
Number of subjects: 2132

Group type: EXPERIMENTAL
Intervention: Regional anaesthesia‐analgesia
Number of subjects: 2132

Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 2132
Study: 28196046

Group type: EXPERIMENTAL
Intervention: Test (new oral formulation of levosulpiride, tablet 25 mg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Reference (commercially available formulation, tablet 25 mg)
Number of subjects: 32
Study: 25355797

Group type: EXPERIMENTAL
Intervention: Nonadjuvanted whole‐virus G9 lineage H9N2 influenza virus vaccine (doses ranging from 3.75 to 45 μg of hemagglutinin antigen)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nonadjuvanted whole‐virus G9 lineage H9N2 influenza virus vaccine
Number of subjects: 0
Study: 24292351

Group type: EXPERIMENTAL
Intervention: BOO (1(3)‐behenoyl‐2,3(1)‐dioleoyl‐rac‐glycerol) intake of 2.46 g/day for 7 days
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (soft cookies containing margarine without BOO)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: BOO (1(3)‐behenoyl‐2,3(1)‐dioleoyl‐rac‐glycerol)
Number of subjects: 14
Study: 20886556

Group type: EXPERIMENTAL
Intervention: LOH on 17p13.1
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: LOH on 4q
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: LOH on 8p
Number of subjects: 37
Study: 18720880

Group type: COMPARATOR
Intervention: Moderate and severe OSAHS
Number of subjects: 60

Group type: COMPARATOR
Intervention: Mild OSAHS
Number of subjects: 60
Study: 16443423

Group type: EXPERIMENTAL
Intervention: Progestin-containing groups
Number of subjects: 221

Group type: COMPARATOR
Intervention: Conjugated equine estrogen-only group
Number of subjects: 221
Study: 12763175

Group type: EXPERIMENTAL
Intervention: Recombinant activated Protein C (alpha‐drotrecogin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recombinant TFPI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AT concentrates
Number of subjects: 0
Study: 10480191

Group type: EXPERIMENTAL
Intervention: 0.3 mg of cerivastatin sodium once daily
Number of subjects: 73

Group type: COMPARATOR
Intervention: 0.15 mg of cerivastatin sodium once daily
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: 0.3 mg of cerivastatin sodium
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Combined results of 0.3 mg and 0.15 mg groups
Number of subjects: 73
Study: 8620266

Group type: EXPERIMENTAL
Intervention: Provider prompt/reminder
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Computer-assisted treatment planner
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Interactive patient education/therapy
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Patient prompt/reminder
Number of subjects: 98
Study: 1906020

Group type: EXPERIMENTAL
Intervention: Flare-up ovarian stimulation protocol for patterns A and B
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Early luteal phase Lupron protocol for pattern C
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: High pure FSH flare-up protocol for pattern D
Number of subjects: 80
Study: 7065943

Group type: EXPERIMENTAL
Intervention: 6% DMC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 9% DMC
Number of subjects: 0

Group type: COMPARATOR
Intervention: 1% pilocarpine
Number of subjects: 0
Study: 31344257

Group type: EXPERIMENTAL
Intervention: Audiovisual stimulation
Number of subjects: 160

Group type: COMPARATOR
Intervention: Histamine iontophoresis
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 160
Study: 29807661

Group type: EXPERIMENTAL
Intervention: Stress-induced cortisol reactivity
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-stress control
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cortisol non-responders
Number of subjects: 0
Study: 28275044

Group type: EXPERIMENTAL
Intervention: HemoCue Hb 301 devices
Number of subjects: 2846

Group type: EXPERIMENTAL
Intervention: Device operators
Number of subjects: 2846
Study: 26520401

Group type: EXPERIMENTAL
Intervention: Parenteral artesunate at 2.4 mg/kg at H0, H12, H24 and then once daily (ARTES)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Loading dose of quinine base at 16.6 mg/kg followed by maintenance dose of 8.3 mg/kg (QLD)
Number of subjects: 116

Group type: COMPARATOR
Intervention: 8.3 mg/kg quinine base every 8 hours (QNLD3)
Number of subjects: 116

Group type: COMPARATOR
Intervention: 12.5 mg/kg quinine base every 12 hours (QNLD2)
Number of subjects: 116
Study: 24455828

Group type: EXPERIMENTAL
Intervention: Glu-OC in hemodialysis patients
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Gla-OC in hemodialysis patients
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Correlation of Glu-OC with iPTH, bALP, TRAP5
Number of subjects: 68
Study: 22021142

Group type: EXPERIMENTAL
Intervention: PHILOS alone (Group A)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: PHILOS augmentation plus minimally invasive injectable graft (MIIG) X3 Hivisc (Group B)
Number of subjects: 50
Study: 18723296

Group type: EXPERIMENTAL
Intervention: Concurrent cisplatin-based chemotherapy (Group 3)
Number of subjects: 422

Group type: COMPARATOR
Intervention: Basic radiotherapy course alone (Group 1)
Number of subjects: 422

Group type: COMPARATOR
Intervention: Additional boost of 5 Gy in 2 fractions (Group 2)
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: Age and concurrent chemotherapy
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: Radiation dose to the cochlea
Number of subjects: 422
Study: 16925684

Group type: EXPERIMENTAL
Intervention: Allergoid immunotherapy
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control (no immunotherapy)
Number of subjects: 53
Study: 15503655

Group type: EXPERIMENTAL
Intervention: Ezetimibe + simvastatin (Vytorin)
Number of subjects: 0
Study: 11322745

Group type: EXPERIMENTAL
Intervention: Risperidone (mean dose at treatment endpoint = 0.05 mg/kg; mean total dose = 1.2 mg/day)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 9165504

Group type: EXPERIMENTAL
Intervention: High-dose toremifene (200 or 240 mg/d)
Number of subjects: 733

Group type: COMPARATOR
Intervention: Tamoxifen (20 or 40 mg/d)
Number of subjects: 733